AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: Induction chemotherapy: 10 mg/m\^2 day continuous intravenous (CIV) days 1-3
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Induction chemotherapy: 50 mg/m\^2 day continuous intravenous days 1-3
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Induction chemotherapy: 25 mg/m\^2 day intravenous days 1-3 Transplant: 30 mg/m\^2 day x 4 days (days -6, -5, -4, -3 )
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg/m\^2 day 1-4
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Induction chemotherapy: 0.5 mg/m\^2 day continuous intravenous days 1-3
Study NCT00006184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Transplant: 5 mg/m\^2 intravenous on days +1, +3, +6, +11
Study NCT00006184 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: GMCSF (granulocyte macrophage colony stimulating factor)
Description: 250 mcg/m\^2 subcutaneously every day, days 1-4
Study NCT00006184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GCSF (granulocyte colony stimulating factor)
Description: 10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) > 1000/ul x 2 days
Study NCT00167934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Depakote ER 500 mg to 3000 mg taken every night
Study NCT00167934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given at same frequency as Valproate
Study NCT03357406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound implant site preparation
Description: piezoelectric bone surgery will be used to create implant bone ostectomy
Study NCT03357406 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional implant site preparation
Description: twist drills will be used to create implant bone ostectomy
Study NCT00581282 — intervention group
Intervention type: RADIATION
Intervention: PET scan
Description: positron emission tomography PET scan
Study NCT00581282 — intervention group
Intervention type: OTHER
Intervention: fMRI
Description: functional magnetic resonance imaging fMRI
Study NCT02730416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib or Placebo; Carboplatin, Paclitaxel
Description: Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
Study NCT02730416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nintedanib or Placebo; Carboplatin, Paclitaxel
Description: Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
Study NCT02677337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: chart abstraction
Description: chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
Study NCT01020019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol: 20 mg/TID
Study NCT01020019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT01020019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofex: .6 mg/ TID
Study NCT01121211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone 300mcg transdermal patch x 24 weeks.
Study NCT01121211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patch x 24 weeks
Study NCT00861211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senicapoc
Description: Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
Study NCT02677337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Program
Study NCT02988310 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00956813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed
Description: Given orally
Study NCT00956813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00861211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT03536039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: dose of 0.8 mcg/sqm
Study NCT03536039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RITUXIMAB
Description: dose of 375 mg/mq
Study NCT03536039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: dose of 50 mg/mq
Study NCT03536039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: dose of 750 mg/mq
Study NCT03536039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: dose of 1.4 mg/mq (max 2 mg)
Study NCT03536039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 75 mg
Study NCT03940742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT03940742 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirzepatide
Description: Administered SC
Study NCT00709904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery
Study NCT00709904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery
Study NCT00709904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Semuloparin sodium)
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily
Study NCT03640676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: FlowOx
Description: FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
Study NCT03640676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowOx
Description: FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
Study NCT03306264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 oral tablet
Study NCT03306264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen
Description: Decitabine 20 mg/m\^2 one-hour IV infusion
Study NCT00709904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: 0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily
Study NCT04137926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MicRNAs battery
Description: for MCI due to AD diagnosis
Study NCT00448929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OculusGen Biodegradable Collagen Matrix Implant
Description: Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
Study NCT03861689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI pelvis
Description: MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract within 24 months if the anatomy of the fistula is favourable
Study NCT00928629 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ankle-brachial index (ABI) Screening Test
Description: Patients will undergo an ABI measurement
Study NCT03727113 — intervention group
Intervention type: PROCEDURE
Intervention: Optimization cohort
Description: Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
Study NCT03727113 — intervention group
Intervention type: PROCEDURE
Intervention: Control cohort
Description: Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
Study NCT03011385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Planning
Description: Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning.
Study NCT03011385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Planning
Description: Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
Study NCT03011385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Planning
Description: Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
Study NCT03026621 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lignite Extract
Description: The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo.
Study NCT03026621 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Herbal tea
Description: This is an herbal tea that will look like the control
Study NCT03011385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
Study NCT03011385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
Study NCT03251248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB11455
Description: Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
Study NCT03251248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta
Description: Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
Study NCT03306888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching
Description: Physical activity coaching over 4 months
Study NCT01211275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: axitinib
Description: axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
Study NCT01211275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
Study NCT04510935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia
Description: the patient will receive general anesthesia during surgery in this group.
Study NCT04510935 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: the patient will receive local anesthesia during surgery in this group.
Study NCT03528434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 10mg dispersible zinc sulfate tablet
Study NCT01862679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis
Description: High-flux haemodialysis is the standard dialysis modality currently in use in the UK
Study NCT03528434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispersible tablet with inert ingredients, identical to zinc in appearance
Study NCT00333606 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Body acupuncture of 1 specific point per trial session
Study NCT00333606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Body acupuncture of 1 specific point per trial session
Study NCT03411525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commitment Invitation for Clinicians (Clinician Intervention)
Description: Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
Study NCT03411525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Education Materials to Patients (Patient Intervention)
Description: During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
Study NCT01862679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration
Description: During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood.
Study NCT03282552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula High Flow Oxygen
Description: Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
Study NCT00653354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
Study NCT00653354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib/placebo
Description: valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Study NCT00653354 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
Study NCT03291613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinpoint App
Description: Tablet app with pain assessment and communication education, and pain assessment tool.
Study NCT01155895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine Besylate / Benazepril Hydrochloride
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
Study NCT01155895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine Besylate / Benazepril Hydrochloride
Description: 10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
Study NCT00658112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide
Description: Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
Study NCT01027169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: safinamide
Description: single dose of 50mg safinamide on Day 1
Study NCT06048471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HiTop
Description: High tone transcutaneous electrical stimulation
Study NCT06048471 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HiTop
Description: High tone transcutaneous electrical stimulation
Study NCT00014235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study NCT00014235 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00556842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
Study NCT00556842 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemi-arthroplasty
Description: Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
Study NCT03673137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Description: During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
Study NCT02210429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Elbow Fracture Fixation